Kidney Transplant Rejection - Pipeline Insight, 2025

This “Kidney Transplant Rejection - Pipeline Insight, 2025” report provides comprehensive insights about 6+ companies and 8+ pipeline drugs in Kidney Transplant Rejection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Kidney Transplant Rejection: Understanding

Kidney Transplant Rejection: Overview

Kidney transplant rejection occurs when the recipient's immune system identifies the transplanted kidney as a foreign object and mounts an immune response against it. This response can damage the kidney, impairing its function and potentially leading to transplant failure. Rejection is a significant concern in transplant medicine, as it can occur at any time post-transplant, from days to years after the surgery. The body's immune system, designed to protect against harmful invaders like bacteria and viruses, can mistakenly target the transplanted organ because it recognizes the donor kidney's tissues as non-self.

There are three main types of kidney transplant rejection: hyperacute, acute, and chronic. Hyperacute rejection happens within minutes to hours after the transplant and is usually caused by pre-existing antibodies in the recipient that immediately attack the donor kidney. Acute rejection occurs within the first few months post-transplant and is more common, driven by the recipient's T cells attacking the donor kidney. Chronic rejection is a longer-term issue, developing over months to years, and involves gradual loss of kidney function due to prolonged immune response and other factors such as hypertension and recurrent infections. Each type requires different strategies for prevention and management to ensure the longevity and function of the transplanted kidney.

Prevention and treatment of kidney transplant rejection rely heavily on immunosuppressive medications, which are prescribed to weaken the recipient's immune response and reduce the risk of rejection. These medications must be carefully balanced to avoid under-suppressing the immune system, which can lead to rejection, and over-suppressing it, which can make the recipient vulnerable to infections and other complications. Regular monitoring of kidney function through blood tests and biopsies is essential to detect early signs of rejection and to adjust treatment protocols promptly. Advances in immunosuppressive therapies and a better understanding of the immune mechanisms involved in rejection have significantly improved the outcomes for kidney transplant recipients.

'Kidney Transplant Rejection- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Kidney Transplant Rejection pipeline landscape is provided which includes the disease overview and Kidney Transplant Rejection treatment guidelines. The assessment part of the report embraces, in depth Kidney Transplant Rejection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Kidney Transplant Rejection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Kidney Transplant Rejection R&D. The therapies under development are focused on novel approaches to treat/improve Kidney Transplant Rejection.

Kidney Transplant Rejection Emerging Drugs Chapters

This segment of the Kidney Transplant Rejection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Kidney Transplant Rejection Emerging Drugs

AT-1501: Eledon Pharmaceuticals

AT-1501 (also known as tegoprubart) is a promising monoclonal antibody that has shown potential for preventing organ rejection in kidney transplant recipients. The antibody was engineered to minimize the risk of blood clots, which had been problematic with earlier versions of this therapy. Currently, the drug is in Phase II stage of its clinical trial evaluation for Kidney Transplant Rejection.

TX200: Sangamo Therapeutics

TX200 is a CAR-Treg cell therapy developed by Sangamo Therapeutics for the prevention of immune-mediated rejection in kidney transplantation. TX200 is composed of autologous Treg cells engineered to express an HLA-A2 CAR. These cells are collected from the patient, genetically engineered, and then cryopreserved. The therapy is designed to accumulate in the transplanted kidney where the HLA-A2 protein is present, suppressing immune responses against the graft. This aims to induce immunological tolerance and potentially reduce or eliminate the need for lifelong immunosuppressive medications. Currently, the drug is in the Phase I/II stage of development to treat Kidney Transplant Rejection.

Kidney Transplant Rejection: Therapeutic Assessment

This segment of the report provides insights about the different Kidney Transplant Rejection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Kidney Transplant Rejection

• There are approx. 6+ key companies which are developing the therapies for Kidney Transplant Rejection. The companies which have their Kidney Transplant Rejection drug candidates in the most advanced stage, i.e. Phase II include, Eledon Pharmaceuticals.

Phases

The report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Kidney Transplant Rejection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Kidney Transplant Rejection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Kidney Transplant Rejection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Kidney Transplant Rejection drugs.

Kidney Transplant Rejection Report Insights

• Kidney Transplant Rejection Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Kidney Transplant Rejection Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Kidney Transplant Rejection drugs?
• How many Kidney Transplant Rejection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Kidney Transplant Rejection?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Kidney Transplant Rejection therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Kidney Transplant Rejection and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Eledon Pharmaceuticals
• Sangamo Therapeutics
• LIS1

Key Products

• AT-1501
• TX200
• Xenothera SAS

This product will be delivered within 2 business days.